Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Masked, Two-Part, Placebo-Controlled Phase 2A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Masked, Two-Part, Placebo-Controlled Phase 2A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clobetasol (Primary)
  • Indications Ocular inflammation; Ocular pain; Postoperative inflammation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Formosa Pharmaceuticals

Most Recent Events

  • 28 Apr 2022 Results presented in the Formosa Pharmaceuticals Media Release.
  • 28 Apr 2022 According to a Formosa Pharmaceuticals media release, data from this study will be presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) by Dr. Jeffrey Levenson.
  • 09 Jun 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top